Mercury Pharma Group Limited; Erwerb des gesamten ausgegebenen Aktienkapitals und der alleinigen Kontrolle über bestimmte Gesellschaften der Intercept Pharmaceuticals (USA)

On 12.05.2022 the Austrian Federal Competition Authority was notified of the following merger:

Planned purchase process

Mercury Pharma Group Ltd., ultimately owned and controlled by Advanz Pharma Group, which itself is ultimately controlled by certain Nordic Capital XFunds, intends
to acquire the ex-US Ocaliva® (obeticholic acid) business from US-based Intercept Pharmaceuticals. Obeticholic acid is used as a second line therapy for the treatment of
primary biliafy cholangitis, a rare liver disease.
Business sector concerned: Manufacture of basic pharmaceutical products and pharmaceutical preparations.

Industry sector: C - Verarbeitendes Gewerbe/Herstellung von Waren

Deadline for bringing in an application pursuant to § 11(1) Cartel Act will end on 09.06.2022.

Entrepreneurs whose legal or economic interests are affected by the merger can bring in a written statement at the Federal Competition Authority or the Federal Cartel Prosecutor within 14 days from publication date.

Note: The intervening party has no right to a certain treatment of the statement and will not gain a party position.

back to list